InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,782.42
(
-0.02%
)
Post# of 68825
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Krysti

Send PM Follow Ignore
Followers 39
Posts 2702
Boards Moderated 0
Alias Born 09/20/2010

Krysti

Re: Cycle40 post# 66441

Thursday, 07/21/2016 5:26:54 AM

Thursday, July 21, 2016 5:26:54 AM

Post# of 68825
A REVO extension patent was issued to Eyetalk365.

Ron Carter is shown as the inventor of the improvements, but the patent has been issued to Eyetalk365.

This means that Ron Carter now works for Eyetalk, and not REVO.

Which means that REVO shareholders will see as much from this patent as they have seen from the others.

The grand total of royalties REVO has received from Eyetalk365 is $nil. $nothing. $nichts....

...As Eyetalk is, presumably, receiving money from royalties.

That doesn't sound like a 60:40 split.

Something smell fishy to you?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up